Skip to search formSkip to main contentSkip to account menu

vatalanib

Known as: 1-(4-chloroanilino)-4-(pyridylmethyl)phthalazine, N-(4-Chlorophenyl)-4-(4-pyridinylmethyl)-1-phthalazinamine, PTK/ZK 
An orally bioavailable anilinophthalazine with potential antineoplastic activity. Vatalanib binds to and inhibits the protein kinase domain of… 
National Institutes of Health

Related topics

Related topics

14 relations

Narrower (4)

CGP79787DPTK 787PTK787/ZK 222584ZK 222584
FLT1 protein, humanNCIt Antineoplastic Agent TerminologyReceptor Tyrosine Kinase InhibitionVascular Endothelial Growth Factor Receptor 2, human

Broader (3)

PhthalazinesProtein Kinase InhibitorsPyridines

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2011
Review
2011
Antiangiogenic therapies in epithelial ovarian cancer.
BACKGROUND Angiogenesis is a critical component of tumor development and proliferation, and increased angiogenesis has been… 
2011
2011
Vatalanib in advanced colorectal cancer: two studies with identical results.
Because of biologic variability, limited impact of treatment, chance, and sometimes bias, the results of clinical trials in… 
2010
2010
Phase 1 study of combination treatment with PTK 787/ZK 222584 and cetuximab for patients with advanced solid tumors: safety, pharmacokinetics, pharmacodynamics analysis.
INTRODUCTION PTK/ZK is a small-molecule inhibitor of all three vascular endothelial growth factor (VEGF) receptors, platelet… 
2008
2008
Open-label, non-randomized, multicenter phase II study evaluating the angiogenesis inhibitor PTK787/ ZK222584 (PTK/ZK) in patients with advanced neuroendocrine carcinomas (NEC)
2007
2007
PTK787/ZK 222584, a small molecule tyrosine kinase receptor inhibitor of vascular endothelial growth factor (VEGF), has modest activity in myelofibrosis with myeloid metaplasia.
Highly Cited
2005
Highly Cited
2005
Soluble markers for the assessment of biological activity with PTK787/ZK 222584 (PTK/ZK), a vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor in patients with advanced…
BACKGROUND Plasma and serum biomarkers of angiogenesis and activated endothelial cells were evaluated to assess biological… 
Highly Cited
2005
Highly Cited
2005
PTK787/ZK222584, a tyrosine kinase inhibitor of vascular endothelial growth factor receptor, reduces uptake of the contrast agent GdDOTA by murine orthotopic B16/BL6 melanoma tumours and inhibits…
Assessment of tumour vascularity may characterize malignancy as well as predict responsiveness to anti‐angiogenic therapy. Non… 
Review
2004
Review
2004
A phase I/II trial of single-agent PTK 787/ZK 222584 (PTK/ZK), a novel, oral angiogenesis inhibitor, in patients with recurrent glioblastoma multiforme (GBM).
1512 Background: VEGF-mediated signaling pathways may be critical to GBM neovascularization, and inhibition of VEGF pathways may… 
Highly Cited
2004
Highly Cited
2004
A phase I/II trial of PTK787/ZK 222584 (PTK/ZK), a novel, oral angiogenesis inhibitor, in combination with either temozolomide or lomustine for patients with recurrent glioblastoma multiforme (GBM).
1513 Background: VEGF-mediated signaling through VEGF receptors is integral to GBM neovascularization and therefore an attractive… 
Highly Cited
2004
Highly Cited
2004
Phase I/II study of PTK787/ZK 222584 (PTK/ZK), a novel, oral angiogenesis inhibitor in combination with FOLFIRI as first-line treatment for patients with metastatic colorectal cancer.
3558 Background: Increased angiogenesis is correlated with poor prognosis in patients with advanced metastatic colorectal cancer… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)